التفاصيل البيبلوغرافية
| العنوان: |
New Medications for the Treatment of Diabetes. |
| المؤلفون: |
Garg, Satish K.1 (AUTHOR), Brackett, Scott1 (AUTHOR), Reinicke, Trenton1 (AUTHOR), Hirsch, Irl B.2 (AUTHOR) |
| المصدر: |
Diabetes Technology & Therapeutics. 2020 Supplement1, Vol. 22, pS-149-S-173. 25p. |
| مصطلحات موضوعية: |
*HYPERGLYCEMIA, *DIABETIC nephropathies, *DRUGS, *MEDICAL sciences, *MEDICAL personnel |
| مستخلص: |
Many large databases in the United States and Europe have shown a significant reduction in the lifespan (about a decade) of patients with type 2 diabetes (T2D), primarily due to cardiovascular complications and renal disease. In patients with T1D, dapagliflozin was well tolerated when used as adjunct therapy to adjustable insulin and improved glycemic control without increasing hypoglycemia versus placebo; however, patients did experience more DKA events. Sotagliflozin and dapagliflozin were approved by the European Medicines Agency for patients with BMI >27 kg/m SP 2 sp and insulin doses exceeding 0.5 U/kg/day at initiation as adjunctive treatment for patients with T1D. Change in HbA1c from baseline at week 30 was the primary outcome and was assessed in the full analysis set (all patients randomly allocated to any treatment) using on-treatment data collected before any rescue medication began. In this study, 311 individuals aged <65 and 87 patients aged >=65 years from DUAL II, 326 patients <65 years and 112 patients >=65 years from DUAL III, and 412 patients <65 years and 145 patients >=65 years from DUAL V were evaluated. [Extracted from the article] |
| قاعدة البيانات: |
Academic Search Index |
